Who: AstraZeneca/Amoy Diagnostics
What: Previously partnered on companion diagnostic development for ovarian and breast cancer, AstraZeneca and AmoyDx will attempt to develop such tools for optimizing use of Lynparza in the EU, Japan...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?